CUE - キュ―・バイオファ―マ （Cue Biopharma Inc.） キュ―・バイオファ―マCUEのチャート
CUEの企業情報
| symbol | CUE |
|---|---|
| 会社名 | Cue Biopharma Inc （キュ―・バイオファ―マ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Cue Biopharma Inc is a development-stage immunotherapy company. The Company is focused at developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease. Its Immuno-Oncology pipeline includes CUE-100 Framework and CUE-200 Framework; and autoimmune pipeline includes MHC Class I Program and MHC Class II Program. The CUE-100 Framework restricts the activity of T cell populations. The CUE-200 Framework enables potent long-lived anti-tumor T cell responses. The Autoimmune disease therapy protects the healthy cells from immune attack. キュ―・バイオファ―マは米国のバイオ医薬品企業。がんや自己免疫疾患を治療するヒト免疫系の薬剤の開発に従事する。同社の薬剤候補にはT細胞を改善するCUE-100シリ―ズ、排出されたT細胞を活性化するCUE-200シリ―ズを含む。また、腫瘍の自己免疫疾患の適応症に対処するためのプラットフォ―ムを提供する。本社所在地はマサチュ―セッツ州ケンブリッジ。 Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The company's proprietary platform, Immuno-STAT ™(Selective Targeting and Alteration of T cells) is designed to harness the body's intrinsic immune system without the need for ex vivo manipulation. |
| 本社所在地 | 21 Erie St. Cambridge MA 02139 USA |
| 代表者氏名 | Daniel R. Passeri ダニエル・R・パスジェリ |
| 代表者役職名 | President Chief Executive Officer |
| 電話番号 | +1 617-949-2680 |
| 設立年月日 | 41974 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2018年 |
| 従業員数 | － |
| url | www.cuebiopharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cue |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -29.83774 |
| 終値（lastsale） | 7.2262 |
| 時価総額（marketcap） | 145487006.7692 |
| 時価総額 | 時価総額（百万ドル） 141.13420 |
| 売上高 | 売上高（百万ドル） 0.36300 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 95.34820 |
| 当期純利益 | 当期純利益（百万ドル） -30.27878 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Cue Biopharma Inc revenues increased from $0K to $363K. Net loss increased 91% to $14.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing va increase from $4.1M to $8.4M (expense) General and administrative - Balancing increase from $1.3M to $2.7M (expense). |
CUEのテクニカル分析
CUEのニュース
Cue Biopharma Earnings Perspective: Return On Capital Employed 2023/03/22 14:46:10 Benzinga
Cue Biopharma (NASDAQ: CUE ) brought in sales totaling $151 thousand during Q4 according to data provided by Benzinga Pro . However, earnings decreased 33.2%, resulting in a loss of $14.59 million. In Q3, Cue Biopharma brought in $68 thousand in sales but lost $10.96 million in earnings. What Is ROCE? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and … Full story available on Benzinga.com
Cue Biopharma, Inc. (CUE) Q4 2022 Earnings Call Transcript 2023/03/22 03:00:23 Seeking Alpha
Cue Biopharma, Inc. (NASDAQ:NASDAQ:CUE) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ETCompany ParticipantsDan Passeri - CEOMatteo Levisetti - Chief Medical OfficerKen Pienta -…
Cue Biopharma GAAP EPS of -$0.37 misses by $0.06, revenue of $0.15M beats by $0.05M 2023/03/21 20:28:48 Seeking Alpha
Cue Biopharma press release (CUE): Q4 GAAP EPS of -$0.37 misses by $0.06.Revenue of $0.15M (-98.2% Y/Y) beats by $0.05M.Research and development expenses were $11.3…
Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights 2023/03/21 20:10:00 GlobeNewswire
BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, today reported fourth quarter and full year 2022 financial results.
Cue Biopharma''s Earnings Outlook 2023/03/20 15:01:43 Benzinga
Cue Biopharma (NASDAQ: CUE ) is set to give its latest quarterly earnings report on Tuesday, 2023-03-21. Here''s what investors need to know before the announcement. Analysts estimate that Cue Biopharma will report an earnings per share (EPS) of $-0.31. Cue Biopharma bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com
Cue Biopharma Earnings Perspective: Return On Capital Employed 2023/03/22 14:46:10 Benzinga
Cue Biopharma (NASDAQ: CUE ) brought in sales totaling $151 thousand during Q4 according to data provided by Benzinga Pro . However, earnings decreased 33.2%, resulting in a loss of $14.59 million. In Q3, Cue Biopharma brought in $68 thousand in sales but lost $10.96 million in earnings. What Is ROCE? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and … Full story available on Benzinga.com
Cue Biopharma, Inc. (CUE) Q4 2022 Earnings Call Transcript 2023/03/22 03:00:23 Seeking Alpha
Cue Biopharma, Inc. (NASDAQ:NASDAQ:CUE) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ETCompany ParticipantsDan Passeri - CEOMatteo Levisetti - Chief Medical OfficerKen Pienta -…
Cue Biopharma GAAP EPS of -$0.37 misses by $0.06, revenue of $0.15M beats by $0.05M 2023/03/21 20:28:48 Seeking Alpha
Cue Biopharma press release (CUE): Q4 GAAP EPS of -$0.37 misses by $0.06.Revenue of $0.15M (-98.2% Y/Y) beats by $0.05M.Research and development expenses were $11.3…
Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights 2023/03/21 20:10:00 GlobeNewswire
BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, today reported fourth quarter and full year 2022 financial results.
Cue Biopharma''s Earnings Outlook 2023/03/20 15:01:43 Benzinga
Cue Biopharma (NASDAQ: CUE ) is set to give its latest quarterly earnings report on Tuesday, 2023-03-21. Here''s what investors need to know before the announcement. Analysts estimate that Cue Biopharma will report an earnings per share (EPS) of $-0.31. Cue Biopharma bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com
Cue Biopharma to Present at Two February 2023 Scientific Conferences 2023/02/01 13:00:00 GlobeNewswire
BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that its President and Chief Scientific Officer, Anish Suri, Ph.D., will participate in two scientific conferences this February, the Immuno-Oncology 360 o Summit, taking place February 7-10 in New York, NY, and the Federation of American Societies for Experimental Biology (FASEB) Catalyst Conference , taking place virtually February 8-9, 2023.
Cue biopharma names Matteo Levisetti as new Chief Medical Officer 2023/01/23 13:18:37 Seeking Alpha
Cue Biopharma (CUE) promotes its senior Vice President of clinical development, Matteo Levisetti, M.D., to Chief Medical Officer effective January 17, 2023
Cue Biopharma Announces Chief Medical Officer Transition 2023/01/23 13:00:00 GlobeNewswire
BOSTON, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that Matteo Levisetti, M.D., senior vice president (SVP) of clinical development at Cue Biopharma, has been promoted to Chief Medical Officer (CMO) effective January 17, 2023. Current acting CMO Kenneth Pienta, M.D., has transitioned from his current role and will serve as a clinical advisor to the company effective as of the same date.
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences 2022/11/22 13:00:00 GlobeNewswire
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, announced today that it will take part in two fireside chats, the first at the Piper Sandler 34th Annual Healthcare Conference, to be held November 29-December 1 in New York, and the second at the JMP Securities Hematology & Oncology Summit, to be held virtually December 6-7.
MDB Capital Holdings: Public Ventures LLC Completes First Public Company Financing as a Broker-Dealer for Cue Biopharma, Inc. 2022/11/17 14:08:00 Finanz Nachrichten
DALLAS, TX / ACCESSWIRE / November 17, 2022 / Public Ventures, LLC, a wholly owned subsidiary of MDB Capital Holdings, LLC, completed its first financing as a broker-dealer for Cue Biopharma, Inc. …